Back to search results

Study of ALXN1920 for Primary Membranous Nephropathy

This study is testing a drug called ALXN1920 for adults with Primary Membranous Nephropathy (PMN), a kidney disease. Participants will receive either ALXN1920 or a placebo (an inactive substance) through an injection under the skin. The main goal is to see if ALXN1920 can reduce protein in the urine, measured by a 24-hour urine protein creatinine ratio (UPCR), compared to the placebo after 26 weeks. To join, you must be between 18 and 75 years old, have a confirmed diagnosis of PMN with a positive anti-PLA2R antibody level, and be at high risk for the disease getting worse. The study is currently recruiting about 30 participants.

Study design
This is an interventional study comparing ALXN1920 to a placebo. It plans to enroll 30 adult participants.
What's involved
Participants will receive ALXN1920 or placebo via subcutaneous (SC) infusion and continue their standard of care. Protein in the urine will be measured at the start and at Week 26.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at Week 26.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07157787

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

Recruiting
PHASE2Ages 18–75InterventionalTreatment
Alexion Pharmaceuticals, Inc.
~30 participants
Updated 2026-06-18 on ClinicalTrials.gov
What's tested:ALXN1920Placebo

At a glance

Recruiting sites
35 of 40 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change From Baseline in Proteinuria Based on 24-hour UPCR at Week 26
Measured over Baseline, Week 26

Conditions

Primary Membranous Nephropathy

Explore related trials

Primary Membranous NephropathySecretory Phospholipase A2 Receptor

Where it's being run

40 sites across 12 states
Argentina7
Brazil4
China4
Spain4
United Kingdom4
Australia3
France3
Italy3

Who to contact

Alexion Pharmaceuticals, Inc. (Sponsor)
[email protected]
1-855-752-2356
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants who have a documented diagnosis of PMN, established by positive antiPLA2R antibody level (\> 20 RU/mL) at Screening, which must be confirmed by a central laboratory
Participants are willing to receive the background Standard of Care (SoC)
Participants at high risk for disease progression, defined as:
eGFR60 mL/min/1.73 m2 during Screening calculated by CKD-EPI 2021 creatinine formula
All participants must receive prophylactic treatment with appropriate antibiotics while receiving Rituximab (RTX), and be willing to be vaccinated against Neisseria meningitidis

Exclusion

Documented rapid deterioration of kidney function
History of life-threatening Nephrotic Syndrome within 1 year before Screening
Diagnosis of anti- phospholipase A2 receptor (PLA2R) negative membranous nephropathy (MN) or anti-PLA2R positive MN but Screening serum anti-PLA2R \< 20 RU/mL or kidney disease other than PMN
History of kidney transplant or planned kidney transplant or dialysis during the Treatment Period
History of other solid organ (heart, lung, small bowel, pancreas, or liver) or bone marrow transplant; or planned transplant during the Treatment Period
History or presence of any clinically relevant co-morbidities
History of intolerance or hypersensitivity to ACEi or ARB
Initiation or dose adjustment of SGLT2i within 12 weeks prior to randomization or planned adjustment of GSLT2i dose throughout the treatment period.
Use of traditional Chinese medicines or Chinese proprietary medicines with systemic immunosuppressive properties within 6 months prior to screening.
Use of MRA, or ERA within 12 weeks prior to randomization and throughout the study period

What this trial measures

  • Change From Baseline in Proteinuria Based on 24-hour UPCR at Week 26Baseline, Week 26